Loading
Elicio Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Chudnovsky Yekaterina, was filed 26 Dec 2023.
Elicio Therapeutics, Inc.: what insiders have been doing
Elicio Therapeutics, Inc. belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). 4 insiders have disclosed 5 filings since 23 October 2025.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
No insider has bought Elicio Therapeutics, Inc. shares on the open market in the past twelve months. The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction.
For context, the typical company on the same exchange (median of 3,167 companies) published 24 filings over the same period, against 5 filings here. Our records for Elicio Therapeutics, Inc. go back to 2021, with 13 purchases and 30 sales on the open market in total.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
69
Thresholds
n/a
Buy Volume
€7M
13 ops. · all time
Sell Volume
€6M
30 ops. · all time
Since the insiders bought
- -34.7%Entry US$7.76 · Close at T+365 US$5.07
- -43.8%Entry US$17.60 · Close at T+365 US$9.90
- -33.3%Entry US$12.30 · Close at T+365 US$8.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.56
Analyst consensus
3 analysts1.00/5
US$8.00Target US$13.67(+776%)US$23.00
Income statement
RevenueUS$2M
EBITDA-US$37.3M-1883% margin
Net income-US$39.6M0.0% margin
Valuation
PER (forward)-0.9x
P/Book4.3x
Beta1.98
Balance sheet & cash
Market capUS$42.3M
Total debtUS$14.5M
Free Cash Flow-US$37M
Debt / Equity178%
Profitability & ownership
ROE-774.6%
ROA-77.9%
% insiders26.2%
% institutions20.4%
Last declaration on 3 February 2026
Declarations69 total
73,600 shares0Common StockSEC:0001601485-26-000010:0
24,000 shares0Common StockSEC:0001601485-26-000008:0
20,800 shares0Common StockSEC:0001601485-26-000006:0
25,400 shares0Common StockSEC:0001601485-26-000002:0
362 shares@ US$4.4146.2% of flowCommon StockSEC:0001601485-25-000130:0
3,500,573 shares@ US$5.8174.9% of flowCommon StockSEC:0000950170-25-035494:0
381 shares@ US$4.4153.8% of flowCommon StockSEC:0001601485-24-000109:0
50,000 shares@ US$0.01100.0% of flowCommon StockSEC:0001601485-24-000105:0
1,213,000 shares@ US$5.8125.1% of flowCommon StockSEC:0001209191-23-059683:0
Canonical exit: 21 Mar 2024 (T+90)
32,082 shares@ US$1.124.3% of flowCommon StockSEC:0001601485-22-000059:0
614,310 shares@ US$6.43100.0% of flowCommon StockSEC:0001601485-22-000044:0
396,329 shares@ US$6.4359.1% of flowCommon StockSEC:0001601485-22-000045:0
11,313 shares@ US$1.24661.7% of flowCommon StockSEC:0001601485-22-000043:0
Canonical exit: 23 Aug 2022 (T+90)
32,200 shares@ US$1.240.7% of flowCommon StockSEC:0001601485-22-000039:1
Canonical exit: 22 Aug 2022 (T+90)
50,000 shares@ US$1.237.6% of flowCommon StockSEC:0001601485-22-000039:0
Canonical exit: 18 Aug 2022 (T+90)
2,037 shares@ US$1.1822.0% of flowCommon StockSEC:0001628280-22-015238:1
Canonical exit: 18 Aug 2022 (T+90)
7,346 shares@ US$1.16100.0% of flowCommon StockSEC:0001628280-22-015238:0
Canonical exit: 17 Aug 2022 (T+90)
210,337 shares@ US$2.669.4% of flowCommon StockSEC:0001601485-21-000095:1
Canonical exit: 28 Mar 2022 (T+90)
66,907 shares@ US$2.548619.6% of flowCommon StockSEC:0001601485-21-000095:0
Canonical exit: 27 Mar 2022 (T+90)
3,527 shares@ US$2.54491.0% of flowCommon StockSEC:0001601485-21-000093:0
Canonical exit: 20 Mar 2022 (T+90)
358 shares@ US$2.62013.7% of flowCommon StockSEC:0001601485-21-000091:0
13,742 shares@ US$2.540.6% of flowCommon StockSEC:0001601485-21-000089:1
Canonical exit: 17 Mar 2022 (T+90)
27,883 shares@ US$2.54618.2% of flowCommon StockSEC:0001601485-21-000089:0
Canonical exit: 16 Mar 2022 (T+90)
77,604 shares@ US$2.413.2% of flowCommon StockSEC:0001601485-21-000087:1
Canonical exit: 15 Mar 2022 (T+90)
41,091 shares@ US$13.7861.8% of flowCommon StockSEC:0001601485-21-000087:0
25 of 69 declarations
About Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. is a biopharmaceutical company focused on developing immunotherapeutic treatments for cancer. The company utilizes innovative technology to enhance patients' immune responses.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
